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Abstract
Hypoxia-induced VEGF governs both physiological retinal vascular development and pathological retinal neovascularization. In the current paper, the mechanisms of physiological and
pathological neovascularization are compared and contrasted. During pathological neovascularization, both the absolute and relative expression levels for VEGF164 increased to a greater degree
than during physiological neovascularization. Furthermore, extensive leukocyte adhesion was
observed at the leading edge of pathological, but not physiological, neovascularization. When a
VEGF164-specific neutralizing aptamer was administered, it potently suppressed the leukocyte adhesion and pathological neovascularization, whereas it had little or no effect on physiological
neovascularization. In parallel experiments, genetically altered VEGF164-deficient (VEGF120/188)
mice exhibited no difference in physiological neovascularization when compared with wild-type
(VEGF/) controls. In contrast, administration of a VEGFR-1/Fc fusion protein, which blocks
all VEGF isoforms, led to significant suppression of both pathological and physiological neovascularization. In addition, the targeted inactivation of monocyte lineage cells with clodronateliposomes led to the suppression of pathological neovascularization. Conversely, the blockade of
T lymphocyte–mediated immune responses with an anti-CD2 antibody exacerbated pathological neovascularization. These data highlight important molecular and cellular differences between physiological and pathological retinal neovascularization. During pathological neovascularization, VEGF164 selectively induces inflammation and cellular immunity. These processes
provide positive and negative angiogenic regulation, respectively. Together, new therapeutic approaches for selectively targeting pathological, but not physiological, retinal neovascularization
are outlined.

Introduction

Key words: retina • angiogenesis • VEGF • leukocyte • immunity

Retinal neovascular diseases such as retinopathy of prematurity and proliferative diabetic retinopathy are the major
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causes of neonatal and adult blindness. During both physiological retinal vascular development (1) and pathological
proliferative retinopathy (2), new blood vessel growth is
regulated by vascular endothelial growth factor (VEGF), a
hypoxia-induced endothelial cell–specific mitogen produced in ischemic retinal cells. Although both types of
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neovascularization stem from retinal ischemia, there is an
essential difference in the direction of vessel growth during physiological and pathological neovascularization. In
the former, new vessels extend from the optic disc toward
the peripheral avascular retina, and follow the guidance of
VEGF-expressing retinal astrocytes (2). During pathological neovascularization, although ischemic retinal astrocytes and neurons express VEGF (1), the new vessels invade the vitreous cavity. This ectopic neovascularization
leads to fibrovascular proliferation, resulting in visionthreatening complications, such as vitreous hemorrhage and
traction retinal detachment. Coincident with the pathological neovascularization, the once-vascularized and newly
ischemic central areas of the retina are reinvested with
normal-appearing blood vessels, a process termed “revascularization.” When reagents that block all VEGF isoforms are used, this compensatory intraretinal revascularization is suppressed together with the pathological
neovascularization (3). Thus, ophthalmologists await the
establishment of a new therapy that selectively targets
pathological neovascularization, while sparing compensatory revascularization.
The current paper demonstrates that the differential expression of VEGF164 results in leukocyte adhesion at the
leading edge of pathological, but not physiological, neovascularization. Furthermore, differential functions for the
various leukocyte subpopulations recruited to the sites of
neovascularization are demonstrated here. As a result, new
mechanistic differences are uncovered at the molecular and
cellular levels between the physiological and pathological
neovascularization.

Materials and Methods
Rat Model of Proliferative Retinopathy. All animal experiments
followed the Association for Research in Vision and Ophthalmology guidelines and were approved by the Animal Care Committee of Massachusetts Eye and Ear Infirmary. Long-Evans rats
(Charles River Laboratories) were used. Postnatal day zero (P0)
rats with their nursing mothers were maintained for 10 full days
in 80% oxygen, interrupted daily by 30 min in room air followed
by a progressive return to 80% oxygen, to induce an avascular
retina. On P10 (D0), they were placed in room air for an additional 7 d (D7) to induce retinal neovascularization.
ELISA for VEGF. After sacrifice with an overdose of anesthesia, the eyes were immediately enucleated. The retina was
carefully isolated, placed into 150 l of lysis buffer, and sonicated.
The lysate was centrifuged at 14,000 rpm for 15 min at 4C, and
the VEGF levels in the supernatant were determined with the
Quantikine mouse VEGF ELISA kit (R&D Systems) according to
manufacturer’s protocol. The assay recognizes all VEGF isoforms.
Reverse Transcription (RT)–PCR for VEGF. Total RNA was
isolated from the retina and peripheral monocytes with TRIzol
reagent (Life Technologies), and cDNA was produced using
reverse transcriptase (SuperScript II; Invitrogen). The primer
sequences for GAPDH and rat VEGF were 5-CCATGGAGAAGGCTGGGG-3 (sense) and 5-CAAAGTTGTCATGGATGACC-3 (antisense) for GAPDH and 5-ACCTCCACCATGCCAAGT-3 (sense) and 5-TAGTTCCCGAAACCCTGA-3 (antisense) for VEGF. Analysis of RT-PCR data
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was performed using the intensity ratios of VEGF164/VEGF120 in
each lane.
Lectin Labeling of Retinal Vasculature and Adherent Leukocytes.
The retinal vasculature and adherent leukocytes were imaged by
perfusion-labeling with FITC-coupled Concanavalin A lectin
(Con A; Vector Laboratories) as described previously (4). The flat
mounts were imaged using two epifluorescence microscopes
(models DM RXA and MZ FLIII; Leica), each possessing a different range of magnification.
Intravitreous Injection of Anti-VEGF165 Aptamer (EYE001). After deep anesthesia, an eyelid fissure was created with a fine blade
to expose the eyeball. Intravitreous injections were performed by
inserting a 33-gauge double caliber needle (Ito Corporation) under an operating microscope. Animals received intravitreous injections of 1 l of sterile PBS containing 0.5 nmol of a pegylated
anti-VEGF165 aptamer (EYE001; Eyetech Pharmaceuticals) or
polyethylene glycol (PEG) control. Retinal neovascularization
and leukocyte adhesion were evaluated 7 d after administration in
D0 (P10) retinopathy rats and P3 normal neonates.
The anti-VEGF165 aptamer is an oligonucleotide that binds to
the exon 7–encoded domain of human VEGF165 protein with
high specificity and affinity. The oligonucleotide is conjugated
to a 40-kD PEG moiety to increase its half-life. The aptamer
does not bind to VEGF120(121) and efficiently neutralizes VEGF164
in rats.
Intravitreous Injection of a VEGFR-1/Fc Fusion Protein. Animals received 1-l intravitreous injections of sterile PBS containing 1 g of a mouse VEGFR-1/Fc chimera (R&D Systems) or
an isotype Fc control (R&D Systems). The fusion protein blocks
all VEGF isoforms. A maximal effect dosage (1 g per eye) was
determined and used for comparison with the maximal effect dosage of the anti-VEGF165 aptamer.
Generation of VEGF164-deficient (VEGF120/188) Mice. VEGF/120
male and VEGF/188 female mice, generated previously (5) via
targeted mutagenesis with Cre/loxP–mediated site-specific recombination in embryonic stem cells, were mated to each other.
Sired neonates were genotyped as described previously (5) to select VEGF164-deficient (VEGF120/188) mice and age-matched
wild-type control (VEGF/) mice for analysis at P10.
CD13, CD8, and CD25 Immunofluorescence. Adherent leukocytes were labeled with rhodamine-coupled Con A as described above in the fourth paragraph of Materials and Methods.
Retinal flat mounts were permeabilized with 0.5% Triton X
(Sigma-Aldrich) in PBS for 24 h and nonspecific binding was
blocked with 1% BSA. The retinas were incubated with a FITCconjugated mouse monoclonal antibody against CD13 (clone
WM15, 1:100; Research Diagnostics), CD8 (clone OX-8, 1:100;
Research Diagnostics), or CD25 (clone OX-39, 1:100; Research
Diagnostics) overnight at 4C.
Isolation and Hypoxic Stimulation of Monocytes. Blood was
drawn from D7 rats with retinopathy before sacrifice. The monocytes were purified by positive selection via magnetic cell sorting
(MACS) using MicroBeads conjugated with a monoclonal anti–
rat MHC-II antibody (clone OX-6; Miltenyi Biotec) according
to the manufacturer’s instructions. The isolated monocytes were
seeded at a concentration of 2.5  106 cells per dish and stimulated for 8 h at 37C with 1 or 21% oxygen in a humidified airtight chamber (Modular Incubator Chamber; Billups-Rothenberg). The incubated cells were collected and processed for
RT-PCR for VEGF as described above in the third paragraph of
Materials and Methods.
Intravitreous Administration of Clodronate-liposomes. Clodronate (dichloromethylene diphosphonate) was a gift from Roche
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Diagnostics. Animals with retinopathy received 1-l intravitreous
injections of clodronate- or PBS-liposomes on D0 (P10). The degree of retinal neovascularization was evaluated 7 d later.
Systemic CD2 Blockade. Rats with retinopathy received intraperitoneal injections of 5 mg/kg/day of a mouse anti-rat CD2
neutralizing antibody (clone OX-34; Research Diagnostics) or a
mouse isotype nonimmune antibody (R&D Systems). The reagents were injected for seven consecutive days before evaluation
on D7 (P17).
Endothelial and Lymphocyte Cocultures. Blood was drawn from
D7 rats with retinopathy and age-matched (P17) controls before
sacrifice. Cytotoxic T lymphocytes (CTLs) were purified by positive selection via MACS using MicroBeads conjugated with a
monoclonal anti–rat CD8a antibody (clone G-28; Miltenyi Biotec) according to the manufacturer’s instructions. Human microvascular endothelial cells (Cascade Biologics, Inc.) at passage
6–8 were seeded at a concentration of 2  105 cells per well and
stimulated with 30 ng/ml recombinant human tissue necrosis factor- (TNF-; R&D Systems). Isolated CTLs were incubated for
15 min at 37C with 50 M carboxyfluorescein diacetate succinimidyl ester (CFDASE; Molecular Probes). The fluorescent cells
were washed and incubated (8  105 cells/ml, 100 l per well)
with endothelial monolayers for 4 h, after which nonadherent
lymphocytes were removed and the endothelial monolayer was
washed. To examine whether the apoptosis is FasL-mediated, an
anti–mouse FasL antibody (clone MFL4; BD Biosciences) or an
isotype control antibody (BD Biosciences) was applied at 10 g/
ml for 10 min at 37C to the T cell suspension before the coculture. Cell death was assayed using the TUNEL procedure according to the manufacturer’s instructions (Intergen). Apoptotic cells
were detected using a CD-330 charge-coupled device camera
(Dage-MIT) attached to an epifluorescence microscope (model
MZ FLIII; Leica). A minimum of eight fields each in three separate experiments was analyzed per condition.
Morphometric and Statistical Analysis. All results were expressed
as mean  SD. The number of leukocytes in each flat mount was
counted independently by two investigators under an epifluorescence microscope (DM RXA; Leica). The morphology of the
pathological neovascularization was readily discerned from the intraretinal extension of physiological vessels. The neovascular retinal areas were photographed with an epifluorescence microscope
(MZ FLIII; Leica) and measured using NIH Image. The values
were processed for statistical analyses (Mann-Whitney U test).
Differences were considered statistically significant when the
P values were 0.05.

Results
VEGF Expression in Physiological and Pathological Retinal
Neovascularization. Absolute and relative VEGF isoform
expression levels were studied during both physiological
vascular development (Fig. 1, A and C) and pathological
neovascularization (Fig. 1, B and D). ELISA results showed
that retinal VEGF protein levels were approximately twofold higher in the pathologically neovascularizing retina
(Fig. 1 B) than in the developing retina undergoing physiological neovascularization (Fig. 1 A). RT-PCR showed a
substantial relative difference in VEGF isoform expression
pattern between pathological (Fig. 1 D) and physiological
(Fig. 1 C) neovascularization. The VEGF164/VEGF120 expression ratio was calculated to be 2.2  1.1 in the physio485
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Figure 1. Differential expression of VEGF isoforms during physiological and pathological retinal neovascularization. (A) Retinal VEGF protein
levels (all isoforms) during postnatal development. (B) Retinal VEGF
protein levels after the induction (D0) of pathological neovascularization.
Dotted lines in A and B indicate the constitutive VEGF levels in normal
adult rats. (C) Retinal VEGF mRNA expression during postnatal development. (D) Retinal VEGF mRNA expression after the induction of
pathological neovascularization. The relative expression levels of VEGF164
increased dramatically during pathological neovascularization.

logically developing retinas, and 25.3  8.7 in the pathologically neovascularized retinas.
Existence of Adherent Leukocytes at the Leading Edge of
Pathological, but Not Physiological, Retinal Neovascularization. Leukocyte adhesion was examined at the leading
edge of both physiological and pathological neovascularization. Adherent leukocytes were largely absent at the leading edge of physiological postnatal retinal vascular development (Fig. 2 A). In the retinopathy model of pathological
neovascularization (Fig. 2, B–F), a vast area of avascular retina was formed (Fig. 2 B) during exposure to the hyperoxic
environment (D0). Adherent leukocytes were found in the
revascularizing retina (Fig. 2 C) on D2. These leukocytes
were associated with the incipient pathological neovascular
fronds (Fig. 2 D) on D3. By D7, leukocytes were observed
in the areas of revascularization (Fig. 2 E), but were most
prominent in the pathological neovascular fronds extending
into the vitreous (Fig. 2 F).
Effect of VEGF164-specific Blockade on Physiological and
Pathological Retinal Neovascularization. A VEGF164(165) isoform-specific neutralizing aptamer (EYE001) was used to
determine the role of VEGF164(165) in pathological neovascularization. During pathological neovascularization (Fig.
3, A–F), VEGF164 blockade (Fig. 3 B) led to a significant
inhibition of leukocyte adhesion (Fig. 3 D) and pathological neovascularization (Fig. 3 E). In contrast, little or no
suppression of revascularization (Fig. 3 F) and physiological
neovascularization (Fig. 3, G, H, and J) was observed.
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vasculature (Fig. 4, E–J) were positive for CD13, aminopeptidase N coexpressed with MHC-II for monocyte-surface antigen processing. RT-PCR showed that
circulating monocytes isolated from rats with proliferative
retinopathy expressed VEGF120 and VEGF164, which was
markedly induced after hypoxic stimulation (Fig. 4 K).
T Lymphocytes Are Negative Regulators of Pathological Retinal Neovascularization. To investigate the role of T lymphocytes in pathological neovascularization, a neutralizing
antibody against CD2 was used. CD2 is an important adhesion molecule for T lymphocyte-mediated immune responses, and is also called lymphocyte function-associated
antigen-2 (LFA-2). Notably, compared with nonimmune
control IgG (Fig. 5 A), CD2 blockade (Fig. 5 B) led to significant increase in the pathological neovascularization (Fig.
5 C). Immunohistochemistry confirmed that adherent leuFigure 2. Leukocytes are present at the leading edge of pathological,
but not physiological, retinal neovascularization. (A) No leukocyte adhesion at the leading edge of physiological retinal development on P6. (B–
F) Leukocyte adhesion during the onset and progression of pathological
neovascularization. (B) The formation of extensive retinal ischemia on
D0, immediately after exposure to relative hypoxia (room air). (C)
Abundant inflammatory cells (arrows) randomly adhered to the intraretinal vessels just before the onset of pathological neovascularization. (D)
The leukocyte adhesion (arrows) associated with the incipient vascular
budding on D3. (E) Compared with D0 (B), revascularization proceeded
in concert with pathological neovascularization (arrows) on D7. (F) Leukocyte adhesion (arrows) spatially and temporally associated with vascular
budding. Bars: (A, C, D, and F) 50 m; (B and E) 0.5 mm.

When a VEGFR-1/Fc chimeric protein was used to compare the neutralizing effects of the single VEGF164 isoform
versus all VEGF isoforms, VEGF pan-isoform blockade
(Fig. 3 C) resulted in a significant suppression of leukocyte
adhesion (Fig. 3 D) and pathological neovascularization
(Fig. 3 E). The result was similar to that seen with
VEGF164-specific blockade. However, in contrast to the
VEGF164 inhibition result, a significant suppression of revascularization (Fig. 3 F) and physiological neovascularization (Fig. 3, I and J) was observed with pan-isoform blockade. No difference was detected in physiological and
pathological neovascularization among the following control groups: nontreated, PEG-treated, and Fc-treated rats
(unpublished data). To further confirm the VEGF164 neutralizing effect on retinal vascular development, VEGF164deficient mice were generated and evaluated. No difference in physiological neovascularization was detected
between wild-type (VEGF/) mice and VEGF164-deficient (VEGF120/188) mice (Fig. 3, K–M).
Monocytes Are Positive Regulators of Pathological Retinal
Neovascularization. To investigate the role of monocytes
in pathological neovascularization, clodronate-liposomes
were used to inactivate monocyte lineage cells. Compared
with PBS-liposomes (Fig. 4 A), monocyte-selective depletion (Fig. 4 B) led to a significant suppression of pathological neovascularization (Fig. 4 C), but had negligible effect
on revascularization (Fig. 4 D). Immunohistochemistry
confirmed that a subset of the adherent leukocytes in the
486
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Figure 4. Role of monocytes in pathological retinal neovascularization. (A)
Pathological neovascularization (arrows,
D7) treated with PBS control-liposomes
(n
8) was not inhibited. (B) Pathological
neovascularization (arrows, D7) treated with
clodronate-liposomes (n 8). Notably, the
pathological neovascular budding (C,
PaNV) was suppressed (P 0.01), whereas
revascularization (D, phRV) was not (P
0.05). (E–J) Monocyte adhesion was observed just before and during pathological
neovascularization (H–J). Green fluorescence from the anti-CD13 antibody (E
and H) and red fluorescence from the
rhodamine-coupled Con A (F and I) identifies the Con A–stained cells as being CD13positive leukocytes (arrows) when the images were superimposed (G and J). (K)
Monocyte VEGF mRNA expression in
normoxia (21% oxygen) and hypoxia (1%
oxygen). VEGF levels were markedly increased in response to hypoxic stimulation.
Bars: (E–J) 50 m; (A and B) 0.5 mm.

kocytes at the vascular fronds were positive for CD8 (Fig.
5, D–F) and CD25 (Fig. 5, G–I; IL-2 receptor), indicative
of cytotoxic and activated T lymphocytes, respectively. To
determine whether CD8-positive cytotoxic T lymphocytes
(CTLs) isolated from rats with retinopathy cause a FasLmediated endothelial cell apoptosis, cell death was evaluated using a leukocyte–endothelial coculture system.
Compared with CTLs isolated from age-matched normal
control rats (Fig. 5 J), CTLs from rats with retinopathy
(Fig. 5 K) increased endothelial cell apoptosis (Fig. 5 N).

Figure 3. Effect of VEGF164-specific blockade on physiological and
pathological retinal neovascularization. (A–F) VEGF164-specific blockade
versus VEGF pan-isoform blockade in pathological neovascularization.
(A) Pathological neovascularization (arrows, D7) treated with PEG control
(n
12) was not inhibited. (B) Pathological neovascularization (arrows,
13). (C) Pathological
D7) treated with the anti-VEGF165 aptamer (n
neovascularization (arrows, D7) treated with the VEGFR-1/Fc chimera
(n 10). In addition to the inhibition of leukocyte adhesion to the retinal
vasculature (D, P 0.01), pathological neovascular budding into the vitreous (E, PaNV) was significantly suppressed (P
0.01) via the antiVEGF164 aptamer or the VEGFR-1/Fc. In contrast, the effect of VEGF164
inhibition on physiological revascularization (F, PhRV) was negligible
(P
0.05), but pan-isoform inhibition led to significant suppression of
revascularization (F, P 0.01). Shaded bars indicate comparable values of
age-matched (P17) normal rat neonates (n
8). (G–J) VEGF164-specific
blockade versus VEGF pan-isoform blockade in retinal vascular development. (G) Developing retinal vasculature (P10) treated with PEG control
(n
7). (H) Developing retinal vasculature (P10) treated with antiVEGF165 aptamer (n 8). (I) Developing retinal vasculature (P10) treated
with the VEGFR-1/Fc chimera (n 10). (J) Note the mild suppression
of physiological neovascularization during retinal development via
VEGF164 inhibition, but the substantial suppression via pan-isoform inhibition (P 0.01). (K–M) VEGF164-specific deficiency versus wild type in
retinal vascular development. (K) Developing retinal vasculature (P10) in
wild-type control (VEGF/) mice (n 13). (L) Developing retinal vas13). (M)
culature (P10) in VEGF164-deficient (VEGF120/188) mice (n
VEGF164 deficiency had no significant effect on physiological neovascularization (P 0.05). Bars: (K and L) 0.2 mm; (A–C and G–I) 0.5 mm.
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Administration of a FasL neutralizing antibody (Fig. 5 L),
but not a control nonimmune antibody (Fig. 5 M), led to
significant suppression of the apoptosis caused by the CTLs
isolated from the rats with retinopathy (Fig. 5 N).

Discussion
The current data demonstrate that pathological, but not
physiological, retinal neovascularization is characterized by
the overexpression, both in relative and absolute terms, of
the VEGF164 isoform. The hypoxia-induced VEGF164 isoform expression leads to the recruitment of leukocytes to
sites of pathological neovascularization. These data demonstrate that ischemia-induced neovascularization, classically
thought to be noninflammatory in nature, is characterized
by the influx of inflammatory cells.
Monocyte/macrophage lineage cells express VEGF receptor (R)-1 through which VEGF exerts its chemotactic
actions (6). VEGF also up-regulates the expression of
ICAM-1 on vascular endothelial cells in vitro (7). VEGFinduced blood–retinal barrier breakdown was demonstrated to be leukocyte-dependent, in part, when the inhibition of ICAM-1 prevented blood–retinal barrier
breakdown in VEGF165-injected rat eyes (8). In separate
studies, VEGF-induced endothelial ICAM-1 expression (9)
and vascular leakage (10) were shown to be mediated by
VEGFR-2. Thus, VEGF functions as a proinflammatory
cytokine targeting both leukocytes and endothelial cells.
Taking into account the differential affinity of the VEGF
isoforms for VEGF receptor binding (11, 12), VEGF165
seemed likely to be more responsible for the induction of
inflammation than VEGF121.
The present work is the first to show that adherent leukocytes are associated with the leading edge of pathological,
but not physiological, neovascularization (Fig. 2). The re-
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Figure 5. Role of T lymphocytes in pathological retinal neovascularization. (A) Pathological neovascularization (arrows, D7) treated with
nonimmune isotype control (n
9) showing a similar degree of pathological vascular budding (arrows) compared with Fig. 2 E. (B) Pathological neovascularization (arrows, D7) treated with anti-CD2 antibody (n
11). Notably, the pathological neovascular budding (C, PaNV) was worsened (P 0.01). (D–I) T cell subtypes in pathological neovascular buds.
Green fluorescence from the antibody against CD8 or CD25 (D and G)
and red fluorescence from the rhodamine-coupled Con A (E and H)
identifies the Con A–stained cells as being CD8- and CD25-positive leukocytes (arrows) when the images were superimposed (F and I). (J–N)
Rhodamine-labeled apoptotic cells in the leukocyte–endothelial cocultures were detected via TUNEL staining (red). CTLs were labeled with
CFDASE (green). Compared with control CTLs (J), retinopathy CTLs
(K) significantly increased the number of TUNEL-positive endothelial
cells (N, P
0.01). The process was significantly inhibited via FasL
blockade (L–N, n 18–24 in each condition, P 0.01). Bars: (D–I) 50
m; (J–M) 200 m; and (A and B) 0.5 mm.

cruitment of leukocytes was largely suppressed via VEGF164
isoform-specific blockade (Fig. 3), directly implicating
VEGF164 in the process. Additionally, VEGF164, a more
proinflammatory isoform than VEGF120, was preferentially
induced in pathological neovascularization (Fig. 1). Together, these observations indicate that leukocyte adhesion
in pathological, but not the physiological, neovascularization is properly regarded as a VEGF164-induced pathology.
The current data also show that the selective depletion of
monocyte lineage cells in proliferative retinopathy sup488

presses pathological neovascularization, but not revascularization (Fig. 4). The results mirror those seen after the
VEGF164-specific blockade (Fig. 3). Thus, inflammatory
monocytes appear to facilitate vitreous invasion by the aberrant vasculature. The VEGF164-mediated recruitment of
monocytes just before the appearance of pathological
neovascularization suggests that the monocytes may serve
to mark the sites of future neovascularization (Fig. 2). Indeed, circulating monocytes have a pro-angiogenic potential expressing VEGF164, the production of which is markedly enhanced by hypoxia (Fig. 4). The positive feedback
loop of VEGF164 and monocytes is a potential mechanism
leading to the amplification of pathological neovascularization. Recent in situ hybridization data showing increased
VEGF expression in the ischemic retinal cells (3) and macrophages (13) in the proliferative retinopathy model further
support our conclusions.
VEGF164(165), an isoform more potently mitogenic (11) as
well as more proinflammatory than VEGF120(121), appears to
be sufficient for the physiological neovascularization of retinal development (5). However, VEGF isoforms other than
VEGF164, in combination, may be sufficient to promote
normal physiological neovascularization. Indeed, the complete inhibition of intracellular VEGF signaling was shown
previously to result in substantial suppression of normal vascular development (3) and was reproduced here (Fig. 3),
whereas VEGF164-selective blockade did not affect normal
vascular development (Fig. 3). Consistent with these results,
retinal vascular development was normal in genetically
VEGF164-deficient mice expressing VEGF120 and VEGF188
(Fig. 3; VEGF120/188 mice) in agreement with the aptamerbased VEGF164 neutralization data (Fig. 3). Consequently,
the expression pattern of the various VEGF isoforms,
strictly regulated during normal development but disrupted
in disease, is likely to contribute to an angiogenic switch,
converting the orderly intraretinal extension of vessels into
an inflammation-associated invasion of the vitreous.
The present paper shows that IL-2 receptor (CD25)positive cells and CD8-positive cells adhere to the pathological neovascular fronds (Fig. 5), indicative of the presence of activated CTLs. In a murine tumor model, the
systemic administration of IL-12 and IL-2, both known to
activate cellular immunity, led to the recruitment of FasLpositive CTLs and the inhibition of tumor neovascularization and growth (14). Conversely, an angiogenic role of T
lymphocytes, a source of VEGF, has been suggested in human prostate cancer (15). The present paper demonstrates
that the inhibition of lymphocyte function results in the aggravation of pathological neovascularization (Fig. 5). In our
model of pathological retinal neovascularization, CTLmediated cellular immunity is thought to play a critical role
in the defense against the ectopic proliferation of endothelial cells. This is also supported by the findings that CD8positive T lymphocytes from rats undergoing pathological
neovascularization resulted in the FasL-mediated apoptosis
of endothelial cells in vitro (Fig. 5). The role of immunotherapy for retinal neovascular diseases is currently under
investigation.
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